Immunology Pipeline

Immune Dysregulation Disorders

Immune Dysregulation Disorders

  • AVTX-002 is a fully human monoclonal antibody, directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes). AVTX-002 is currently in Phase 2 development for non-eosinophilic asthma (NEA) (PEAK trial) with proof-of-concept data in inflammatory bowel diseases (IBD) and COVID-19 acute respiratory distress syndrome (ARDS).Learn More >